Edgewise Therapeutics faces challenges with DMD/BMD programs, upcoming trial data concerns, and competitive risks.

Shares of biopharma outfit Edgewise Therapeutics (NASDAQ: EWTX) soared more than 50% today, reaching a three-year high following an update on the clinical testing of its cardiac drug EDG-7500.

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the ...

In this article, we are going to take a look at where Edgewise Therapeutics Inc. (NASDAQ:EWTX) stands against other promising small-cap stocks. Robert Teeter of Silvercrest Asset Management ...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Annual Goldman Sachs Global Healthcare Conference ...

April 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive top-line data of EDG-7500 from the Phase 2 ...

Investors might want to bet on Edgewise Therapeutics, Inc. (EWTX), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates ...

in the first half of 2025 – Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the fourth quarter and full year ...

Within the last quarter, Edgewise Therapeutics (NASDAQ:EWTX) has observed the following analyst ratings: In the last 3 months, 4 analysts have offered 12-month price targets for Edgewise Therapeutics.